For the fourth year in a row, Oxford PharmaGenesis has been listed in the Alantra Pharma Fast 50 as one of the UK’s fastest-growing, privately owned pharmaceutical businesses.
The Pharma Fast 50 report recognizes dynamic and innovative UK pharmaceutical businesses that deliver remarkable growth and are driving the sector forwards. It highlights companies that are passionate about the potential for their businesses to deliver lasting societal change, and that can offer the industry – and the world – a brighter future.
In the report, Tom Cowap (Director – Pharma Services, Alantra) writes: “The leading companies in this field [analytics, insights and communication] have made significant investments of their own, building high-quality teams of people with in-depth expertise and experience of their clients’ therapeutic areas. It is this knowledge that ensures they are able to tell the story of innovation and drug development most effectively.”
Dr Richard White (Chief Operating Officer, Oxford PharmaGenesis) says: “We are proud that Oxford PharmaGenesis has again been recognized for our continued global growth – and that this reflects increased diversity, as well as scale. I’d like to thank all of our great people and clients who have made this possible.”
Read the report here.
